Note: This story has been updated with information from the company's earnings call.
NEW YORK – Meridian Bioscience reported on Friday that its fiscal first quarter revenues increased 96 percent year over year due to the firm's COVID-19 products.
For the three months ended Dec. 31, 2020 the firm reported revenues of $92.9 million, up from $47.4 million a year ago. Meridian beat the average Wall Street estimate of $83.9 million.